EMA Adopts a New Pharmaceutical Form of Selumetinib By Ogkologos - December 16, 2025 455 0 Facebook Twitter Google+ Pinterest WhatsApp It is associated with an extension to the existing indication Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Antitumour Activity of Combination of Lenvatinib and Pembrolizumab in Patients with... August 2, 2022 How radiotherapy became a lifesaver – from X-rays to the proton... July 8, 2022 How to Strengthen Your Immune System: Part 2 September 18, 2020 FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous... March 18, 2026 Load more HOT NEWS New on NCI Websites for October 2018 Color-Blind Groom Sees Color For First Time After Bride Surprises Him... Alex Trebek Admits Undergoing Chemo For Stage 4 Pancreatic Cancer Has... Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients...
